托利德通过阻断刺/Gli通路来抑制上皮卵巢瘤的生长
Lanyan Hu1, Mai Gao2, Huifu Jiang1
1Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China.
Aging
|October 18, 2023
概括
三胺 (TPL) 通过准刺/Gli通路来抑制上皮卵巢癌 (EOC). TPL促进 Gli1 和 Gli2 的降解,减少瘤生长和攻击性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卵巢上皮癌 (EOC) 具有侵略性,预后不佳.
- 刺 (Hh) /Gli信号通路与EOC进展有关.
- 来自中国草药的化合物托利德 (TPL) 在癌症治疗中显示出潜力.
研究的目的:
- 研究TPL如何影响EOC中的Hh/Gli通路活性.
- 确定TPL对EOC生物行为和瘤生长的影响.
主要方法:
- 使用Gli-依赖的光酶记者测试来选天然化合物.
- 评估了TPL对EOC细胞增殖,迁移和入侵的影响.
- 研究了TPL对Gli1和Gli2降解和无处不在的影响.
- 进行了体内研究,以评估TPL在抑制EOC瘤生长中的有效性.
主要成果:
- 在剂量取决的方式中,TPL显著逆转了Smo激动剂SAG诱导的EOC细胞增殖,迁移和入侵.
- TPL通过无处化促进Gli1和Gli2的降解,从而抑制Hh/Gli通路的活性.
- 在体内研究证实了TPL对EOC瘤生长的显著抑制.
结论:
- 通过准Hh/Gli信号通路,TPL有效地抑制了EOC的进展.
- TPL的机制涉及通过无处不在促进Gli1和Gli2降解.
- TPL在体外和体内都显示出对EOC的显著抗瘤活性.
关键词:
Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1 Gli1Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2 Gli2刺是一种刺,刺是一种刺.卵巢癌是发生在卵巢的癌症.三托利化物是什么相关概念视频
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


